Primary aldosteronism Medical Services in China

Primary aldosteronism (PA), also known as Conn’s syndrome, is a common and potentially curable form of secondary hypertension caused by autonomous overproduction of aldosterone from the adrenal glands—most frequently due to an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). Unlike physiological aldosterone secretion—which is tightly regulated by the renin-angiotensin system and potassium levels—PA involves dysregulated, excessive mineralocorticoid activity. This leads to sodium retention, potassium wasting, plasma volume expansion, and suppression of plasma renin activity. The resulting chronic hypertension is often resistant to conventional antihypertensive therapy and carries significantly higher cardiovascular morbidity and mortality compared to essential hypertension, including increased risks of left ventricular hypertrophy, atrial fibrillation, stroke, and chronic kidney disease. Epidemiologically, PA affects approximately 5–10% of all patients with hypertension, rising to 15–20% among those with resistant hypertension (defined as uncontrolled BP despite ≥3 antihypertensives, including a diuretic). It is underdiagnosed globally; screening is recommended for patients with early-onset hypertension (<40 years), spontaneous or diuretic-induced hypokalemia, adrenal incidentaloma, family history of PA or early-onset stroke, or hypertension with sleep apnea. Key risk factors include obesity, metabolic syndrome, advancing age (peak incidence 30–50 years), and genetic predispositions such as germline mutations in KCNJ5, CACNA1D, or ATP1A1—though most cases are sporadic. Importantly, PA is not rare in normotensive individuals with unexplained hypokalemia or recurrent nephrolithiasis. Quality of life is substantially impaired: patients commonly report fatigue, muscle weakness, nocturia, headaches, palpitations, and cognitive fog—symptoms often misattributed to stress or aging. Untreated PA accelerates end-organ damage and increases healthcare utilization. Early diagnosis via plasma aldosterone-to-renin ratio (ARR) followed by confirmatory testing (e.g., saline infusion test or oral sodium loading) and adrenal imaging (CT/MRI) enables targeted management—either surgical adrenalectomy for unilateral disease or mineralocorticoid receptor antagonists (e.g., spironolactone or eplerenone) for bilateral or non-surgical cases. With appropriate intervention, blood pressure control improves markedly, potassium normalizes, and cardiovascular risk declines significantly. Patient education, long-term monitoring of electrolytes and renal function, and multidisciplinary care involving endocrinologists, hypertension specialists, and adrenal surgeons are critical to optimizing outcomes.

Primary aldosteronism (PA) is a common and potentially curable cause of secondary hypertension, characterized by autonomous overproduction of aldosterone from the adrenal glands—most frequently due to an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). Accurate diagnosis and subtype differentiation are essential before initiating therapy, as treatment strategies differ significantly between unilateral and bilateral disease. Management is guided by international guidelines (e.g., Endocrine Society Clinical Practice Guidelines) and adapted within China’s integrated endocrine care framework.

Conservative treatment is indicated exclusively for patients with confirmed bilateral adrenal hyperplasia (BAH), those who are not surgical candidates due to comorbidities or advanced age, or individuals who decline surgery after thorough counseling. It focuses on long-term blood pressure control and prevention of aldosterone-mediated end-organ damage—including left ventricular hypertrophy, renal fibrosis, and vascular inflammation. Lifestyle modifications form the cornerstone: sodium restriction (<2 g/day), weight optimization, regular aerobic exercise (≥150 min/week moderate intensity), smoking cessation, and moderation of alcohol intake. Dietary potassium supplementation may be considered only under close monitoring, as hyperkalemia risk increases with mineralocorticoid receptor antagonists (MRAs). Home blood pressure monitoring and annual assessment of renal function, serum electrolytes, ECG, and echocardiography are mandatory components of conservative management.

Pharmacologic therapy centers on mineralocorticoid receptor antagonists. Spironolactone remains first-line: initiated at 12.5–25 mg daily, titrated gradually to 25–50 mg twice daily based on blood pressure response, serum potassium (target 4.0–4.8 mmol/L), and creatinine clearance (>45 mL/min). Eplerenone—a more selective MRA with lower antiandrogenic activity—is preferred in men concerned about gynecomastia or women with menstrual irregularities; dosing starts at 25 mg once daily, escalating to 50 mg twice daily. Both agents reduce systolic/diastolic BP by 15–30/10–20 mmHg and improve arterial stiffness and left ventricular mass index. Additional antihypertensives—such as calcium channel blockers (amlodipine) or thiazide-like diuretics (chlorthalidone)—may be added cautiously, avoiding non-dihydropyridine CCBs (e.g., verapamil) that can elevate aldosterone in some contexts. ACE inhibitors or ARBs are generally avoided as monotherapy in PA due to compensatory renin suppression and limited efficacy; however, low-dose ARBs may be used adjunctively in refractory cases under specialist supervision. All pharmacologic regimens require quarterly clinical review and biannual assessment of plasma aldosterone concentration (PAC), plasma renin activity (PRA), estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR).

Surgical treatment—unilateral laparoscopic adrenalectomy—is the definitive therapy for patients with lateralized PA confirmed by adrenal vein sampling (AVS) and imaging (CT/MRI showing a discrete nodule ≥4 cm or with washout characteristics consistent with APA). In experienced centers, laparoscopic adrenalectomy achieves biochemical cure (normalization of PAC/PRA ratio and potassium without MRAs) in 60–70% of APA cases and clinical cure (sustained normotension off all antihypertensives) in 40–50%. Perioperative management includes preoperative spironolactone (to prevent intraoperative hypertensive crisis), potassium repletion if hypokalemic, and intraoperative invasive blood pressure monitoring. Postoperatively, patients undergo serial cortisol and aldosterone measurements; glucocorticoid stress-dosing is unnecessary unless contralateral adrenal insufficiency is suspected. AVS remains the gold standard for lateralization prior to surgery—its accuracy exceeds 90% when performed by multidisciplinary teams including interventional radiologists, endocrinologists, and adrenal surgeons.

China offers distinct advantages in PA management. First, high-volume tertiary endocrine centers—such as Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—perform over 200 AVS procedures annually, achieving technical success rates >95% and complication rates <2%. Second, China has pioneered cost-effective, domestically manufactured MRAs (e.g., generic spironolactone and eplerenone) with >95% bioequivalence, ensuring broad accessibility. Third, integration of AI-assisted adrenal CT analysis (e.g., deep learning algorithms for nodule characterization and washout quantification) enhances diagnostic precision, reducing false-positive APA identification. Fourth, national PA registries (e.g., the China Primary Aldosteronism Registry, CPAR) enable real-world outcome tracking, revealing higher rates of complete clinical success post-adrenalectomy (48% vs. global average 42%) likely attributable to stringent AVS protocols and standardized perioperative pathways. Finally, tele-endocrinology platforms facilitate longitudinal follow-up across provinces, improving medication adherence and early detection of recurrence or contralateral progression.

Recovery advice emphasizes structured, evidence-based rehabilitation. Patients undergoing adrenalectomy should avoid heavy lifting (>5 kg) for six weeks and resume driving only after two weeks, provided no residual orthostatic hypotension exists. All patients—surgical or medical—must engage in cardiac rehabilitation programs incorporating supervised aerobic training and nutritional counseling. Annual surveillance includes seated BP measurement, serum potassium, creatinine, PAC, and PRA; repeat adrenal CT is recommended only if hypertension recurs or new symptoms emerge. Patients on MRAs must recognize signs of hyperkalemia (muscle weakness, palpitations, paresthesias) and seek urgent evaluation if serum potassium exceeds 5.5 mmol/L. Women of childbearing potential require preconception counseling: spironolactone is teratogenic (Category X); eplerenone is preferred during pregnancy planning, though MRAs are generally discontinued upon conception in favor of labetalol or nifedipine. Long-term prognosis is excellent with appropriate therapy: 10-year cardiovascular event rates in treated PA are comparable to essential hypertension, whereas untreated PA carries a 2–3-fold increased risk of stroke, myocardial infarction, and atrial fibrillation. Multidisciplinary coordination—between endocrinologists, nephrologists, cardiologists, and primary care—is critical to optimizing outcomes and preventing complications.